# A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

> **NCT07026968** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 815 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- **DRUG:** Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- **DRUG:** Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- **DRUG:** Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- **DRUG:** Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR

## Key facts

- **NCT ID:** NCT07026968
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-11-13
- **Target enrollment:** 815 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07026968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07026968, "A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07026968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*